Elizabeth A. Mittendorf

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  

Elizabeth A. Mittendorf
Nov 13, 2024, 23:18 | Career
Elizabeth A. Mittendorf - Candidate for President Elect for ASCO
Elizabeth A. Mittendorf has been nominated as a Candidate for ASCO President-Elect. The ASCO Nominating…
Nov 2, 2024, 12:01 | Positive
Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…
Oct 18, 2024, 12:10 | Blog
From One-Size-Fits-All to Personalized Treatment: An article by Marleen Kok et al.
Maryam Lustberg shared on LinkedIn: "From One-Size-Fits-All to Personalized Treatment: Challenges and Potential Solutions. Opportunities…
Sep 23, 2024, 09:00 | Insight
Theodoros Kontoulis: Heterogeneity of residual disease (RD) after NACT in breast cancer
Theodoros Kontoulis shared on LinkedIn: “Most viewed in the last 7 days from JAMA Oncology:…
Sep 14, 2024, 19:28 | Insight
Paolo Tarantino: Are all residual diseases equal?
Paolo Tarantino shared on LinkedIn: “ Patients with residual breast cancer after neoadjuvant treatment harbor…
Sep 2, 2024, 17:34 | Blog
Elisabetta Bonzano: Improved efficacy outcomes in early-stage TNBC neoadjuvant ICI therapy
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X: "Neoadjuvant Immune Checkpoint…
Aug 26, 2024, 21:21 | Insight
Integrative Multi-Omic Profiling of Triple Negative Breast Cancer - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X: “This new study examines integrative multi-omic…
Aug 18, 2024, 07:29 | Blog,Opinion
Paolo Tarantino: Do all patients with TNBC need 5 neoadjuvant drugs + 1 year of IO?
Paolo Tarantino shared a post on X about recent paper by Marleen Kok et al., titled…
Jul 29, 2024, 11:19 | Insight
Rasha Aboelhassan: We can give TDM1 in stage I HER2 positive breast cancer
Rasha Aboelhassan shared a post on LinkedIn about a recent paper by Paolo Tarantino et al., commenting:…
Jul 27, 2024, 22:17 | Insight
Commentary led by Marleen Kok highlights all questions in early TNBC post-KN522
Erika Hamilton shared on X: "This commentary led by Marleen Kok highlights all the pertinent…
Jul 26, 2024, 00:03 | Blog
Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522
Elisa Agostinetto shared on X: "Out in JCO a must-read by Marleen Kok on the…
Jul 25, 2024, 08:58 | Insight
Marleen Kok: How do we get from one-size-fits-all to personalized treatment for TNBC
Marleen Kok, Breast Medical Oncologist at the Netherlands Cancer Institute, shared on X: "Today from…
Jul 20, 2024, 11:01 | Insight
Paolo Tarantino: Thanks to ESMO for featuring our 5-year analysis of the ATEMPT randomized phase 3 trial
Paolo Tarantino shared a post on LinkedIn about a paper titled "Adjuvant Trastuzumab Emtansine Versus…
Jul 1, 2024, 15:23 | Insight
Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial
Paolo Tarantino shared a post on X: “Can ADCs help prevent recurrence from breast cancer…
All: 14 Posts: 1 - 100
Special Coverage